Among the 67 patients with HER2-positive breast cancer treated at the RP2D, an ad hoc, exploratory, retrospective analysis was conducted for those patients who were HR+ (ER+ and/or PR+) and those patients who were HR– (ER– and PR–). This evidence concerns the gene ESR1 and breast carcinoma.